Cheaper antibiotics fine for acute sinusitis. (Similar Quality of Life Gains).
The randomized, double-blind study followed patients with uncomplicated acute sinusitis during 2 weeks of treatment and 4 weeks of watching for relapses. After the initial 2 weeks, 8 patients on ceftibuten and 14 on amoxicillin or trimethoprim-sulfamethoxazole (TMP-SMX) had adverse events associated with sinusitis, an insignificant difference between groups, said Dr. Bukstein, Dean Foundation for Health, Research and Education, Madison, Wis. The study was funded by Schering-Plough Corp., which makes ceftibuten.
TMP-SMX was used only for patients who could not take amoxicillin because of penicillin allergy. Five patients in the ceftibuten group and six in the amoxicillin or TMP-SMX group required a second antibiotic after a suboptimal clinical response in the initial 2 weeks, he said at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. The difference between groups was not statistically significant.
Both groups had similarly significant improvements in sleep, non-hay fever symptoms, nasal symptoms, practical problems, activities, and emotions.
Ceftibuten costs about eight times more than amoxicillin or TMP-SMX, so "a huge amount" could be saved if physicians prescribed the cheaper, equally effective antibiotics, Dr. Bukstein said.
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Article Type:||Brief Article|
|Date:||May 1, 2003|
|Previous Article:||Infection control might limit spread of SARS. (Travel History Essential).|
|Next Article:||TB guidelines emphasize patient-centered care. (First Revision Since 1994).|